Manufacturer
Johnson & Johnson
Contents
Nicotine
Indication
For treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.
Advice and support normally improve the success rate.
Instruction
The patient should make every effort to stop smoking completely during treatment with Nicorette Invisi Transdermal Patch. Advice and support normally improve the success rate.
Those Adults and the Elderly: The patch should be applied to an intact area of the skin upon waking up in the morning and removed at bedtime.
Heavy Smokers (Those Smoking 15 or more Cigarettes in a 24-hour Period) are recommended to start at Step 1 with the 25 mg/16 hours patch and use one patch daily for 8 weeks.
Gradual weaning from the patch should then be initiated. One 15 mg/16 hours patch should be used daily for 2 weeks followed by one 10 mg/16 hrs patch daily for 2 weeks.
Light Smokers (Those Smoking less than 15 Cigarettes in a 24-hour Period) are recommended to start at Step 2 with the 15 mg/16 hours patch for 8 weeks and decrease dose to Step 3 (10 mg/16 hours patch) for the final 4 weeks. (See Table 2.)
Drug interaction
Smoking (but not nicotine) is associated with increased activity of CYP1A2. After giving up smoking, clearance of certain medications which are metabolized via CYP1A2 may be reduced. This may lead to increased plasma levels of certain medications. The increase may be of clinical significance for products with narrow therapeutic windows e.g. theophylline, tacrine, clozapine or ropinirole.
Plasma level of other medications which are in part metabolized via CYP1A2 e.g. imipramine, olanzapine, clomipramine and fluvoxamine, might also rise after stop smoking. There are no data supporting this however, and the possible clinical significance of this effect on these medications is unknown.
Limited data indicates that the metabolism of flecainide and pentazocine might also be capable of being induced by smoking.
Malaysia
